EGFR phosphorylates ELK1 through the MEK/ERK pathway, which can activate GDH1 transcription and glutamine degradation, providing a new perspective for changes in glutamine metabolism in tumor cells (Yang et al., 2020). Here, MAP2K7 is linked to neoplasm.